FOXD2 and head and neck cancer: Moreover, the results of public data analysis indicated that increases in FOXD2-AS1 expression levels were clearly discernible between clinical stages, with significantly higher levels in patients with more advanced stage or higher grade of head and neck cancer (Fig. 1b, c).